Based on the enhanced inhibitory efficacy of the co-treatment on the IL-6 signaling pathway activation in RA-FLS, we hypothesized that the combined treatment would have a synergistic negative effect on IL-6-induced hyperactivation of RA-FLS. Here, IL6 is linked to rheumatoid arthritis.